Top

Published in:

01-09-2019 | Chronic Lymphocytic Leukemia | Short Communication

Rituximab dosing in hematological malignancies: an old question, revisited

Authors: Peter N. Morcos, Axel Boehnke, Nancy Valente, Donald E. Mager

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2019

Abstract

Rituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose selection. Extensive clinical pharmacology data collected from the recent subcutaneous development program enabled re-examination of this old question and support that the approved rituximab dosing regimens in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia appear to maximize the clinical benefit in the majority of patients.

Salles G, Barrett M, Foa R et al (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34(10):2232–2273. https://doi.org/10.1007/s12325-017-0612-x. Epub 2017 Oct 5CrossRefPubMedPubMedCentral

Davies A, Berge C, Boehnke A et al (2017) Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther 34(10):2210–2231CrossRefPubMedPubMedCentral

Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) https://www.fda.gov/AdvisoryCommittees/Calendar/ucm547160.htm. Accessed 2 Jan 2019

Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) Roche Briefing package. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm547155.htm. Accessed 20 Mar 2019

Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) FDA Briefing package. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm547155.htm. Accessed 20 Mar 2019

Li J, Zhi J, Wenger M et al (2012) Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol 52:1918–1926CrossRefPubMed

Gibiansky E, Gibiansky L, Carlile DJ et al (2014) Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma and exposure-response in CLL. CPT Pharmacomet Syst Pharmacol 29;3:e144. https://doi.org/10.1038/psp.2014.42 CrossRef

Berinstein NL, Grillo-López AJ, White CA et al (1998) Association of serum rituximab (IDECC2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9(9):995–1001CrossRefPubMed

Gibiansky E, Brewster M, Chavanne C et al (2015) Comparison of population PK and exposure-response relationships of intravenous rituximab and subcutaneous rituximab in patients with CLL. Poster session presented at: 2015 PAGE annual meeting, June 2–5, Hersonissos, Crete, Greece

10.

Dayde D, Ternant D, Ohresser M et al (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113(16):3765–3772. https://doi.org/10.1182/blood-2008-08-175125 (Epub 2008 Nov 24) CrossRefPubMed

11.

Yin A, Li J, Hurst D et al (2010) Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin’s lymphoma. J Clin Oncol 28(suppl 15):e13108CrossRef

12.

Maloney DG, Grillo-López AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMed

13.

Lazzarino M, Arcaini L, Orlandi E et al (2005) Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. Oncology 68:146–153CrossRefPubMed

14.

Gordan LN, Grow WB, Pusateri A et al (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096–1102CrossRefPubMed

15.

Igarashi T, Kobayashi Y, Ogura M et al (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 13:928–943CrossRefPubMed

16.

Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821–830CrossRefPubMed

17.

Jäger U, Fridrick M, Zeitlinger M et al (2012) Rituximab serum concentrations during immunochemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 97:1431–1438CrossRefPubMedPubMedCentral

18.

Kamisoglu K, Phipps A, Jamois C et al (2017) Greater efficacy and potency of obinutuzumab compared with rituximab in chronic lymphocytic leukemia patients confirmed by a semi-mechanistic pharmacokinetic/pharmacodynamic model. Blood 130(Suppl 1):1267. http://www.bloodjournal.org/content/130/Suppl_1/1267. Accessed 2 Jan 2019

Title: Rituximab dosing in hematological malignancies: an old question, revisited
Authors: Peter N. Morcos
Axel Boehnke
Nancy Valente
Donald E. Mager
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Chronic Lymphocytic Leukemia
Rituximab
Rituximab
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03818-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer

The role of thioredoxin system in cancer: strategy for cancer therapy

A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer

The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients

In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models

Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer